1
|
Kumar R, Kumar A, Ram S, Angeli A, Bonardi A, Nocentini A, Gratteri P, Supuran CT, Sharma PK. Novel benzenesulfonamide-bearing pyrazoles and 1,2,4-thiadiazoles as selective carbonic anhydrase inhibitors. Arch Pharm (Weinheim) 2022; 355:e2100241. [PMID: 34596922 DOI: 10.1002/ardp.202100241] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2021] [Revised: 08/28/2021] [Accepted: 09/13/2021] [Indexed: 11/11/2022]
Abstract
Two series comprising 20 novel benzenesulfonamides bearing thioureido-linked pyrazole 8 and amino-1,2,4-thiadiazole 10 were synthesized and assayed as human carbonic anhydrase (hCA) inhibitors against isoforms I and II as well as the tumor-associated isoforms IX and XII. Molecular modeling studies of some potent derivatives (8a, 8c, 10a, and 10c) were also performed against isoforms hCA I, II, and XII. Both the promising series of compounds were synthesized by using commercially available mtethyl ketones and sulfanilamide as the starting materials. Interestingly, this paper also reports a novel methodology for the synthesis of amino-1,2,4-thiadiazoles 10 using 3-amino isoxazoles and 4-isothiocyanatobenzenesulfonamide as reactants. The activity profile of all the newly synthesized compounds reveals that amino-linked 1,2,4-thiadiazoles 10 were better inhibitors of the cytosolic isoform, hCA I, as compared to thioureido-linked pyrazoles 8. Further, hCA II was strongly inhibited by nearly all the newly synthesized sulfonamides, while all the compounds were less effective as hCA IX and XII inhibitors compared to the standard drug acetazolamide. However, in terms of selectivity, compound 8e was found to be the most selective inhibitor of hCA II, which is the isoform associated with glaucoma, edema, altitude sickness, and epilepsy.
Collapse
Affiliation(s)
- Rajiv Kumar
- Department of Chemistry, Kurukshetra University, Kurukshetra, India
- Department of Chemistry, Ch. Mani Ram Godara Government College for Women, Bhodia Khera, Fatehabad, India
| | - Amit Kumar
- Department of Chemistry, Kurukshetra University, Kurukshetra, India
| | - Sita Ram
- Department of Chemistry, Kurukshetra University, Kurukshetra, India
- Department of Chemistry, J. C. Bose University of Science and Technology, YMCA, Faridabad, India
| | - Andrea Angeli
- NEUROFARBA Department-Pharmaceutical and Nutraceutical Section, University of Florence, Polo Scientifico, Firenze, Italy
| | - Alessandro Bonardi
- NEUROFARBA Department-Pharmaceutical and Nutraceutical Section, University of Florence, Polo Scientifico, Firenze, Italy
- Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, Laboratory of Molecular Modelling Cheminformatics & QSAR, University of Florence, Polo Scientifico, Firenze, Italy
| | - Alessio Nocentini
- NEUROFARBA Department-Pharmaceutical and Nutraceutical Section, University of Florence, Polo Scientifico, Firenze, Italy
- Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, Laboratory of Molecular Modelling Cheminformatics & QSAR, University of Florence, Polo Scientifico, Firenze, Italy
| | - Paola Gratteri
- Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, Laboratory of Molecular Modelling Cheminformatics & QSAR, University of Florence, Polo Scientifico, Firenze, Italy
| | - Claudiu T Supuran
- NEUROFARBA Department-Pharmaceutical and Nutraceutical Section, University of Florence, Polo Scientifico, Firenze, Italy
| | - Pawan K Sharma
- Department of Chemistry, Kurukshetra University, Kurukshetra, India
| |
Collapse
|
2
|
Cao XT, Wei SN, Sun HT, Li M, Zheng ZL, Wang G. Iridium-catalyzed regioselective C-H sulfonamidation of 1,2,4-thiadiazoles with sulfonyl azides in water. RSC Adv 2021; 11:22000-22004. [PMID: 35480792 PMCID: PMC9034132 DOI: 10.1039/d1ra04450h] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2021] [Accepted: 06/14/2021] [Indexed: 12/20/2022] Open
Abstract
We have developed a regioselective C-N cross-coupling of 1,2,4-thiadiazoles with sulfonyl azides through iridium catalysis in water. This method tactically linked the 1,2,4-thiadiazoles and sulfonamides together, and the novel molecules increased the diversity of 1,2,4-thiadiazoles which may have potential applications.
Collapse
Affiliation(s)
- Xian-Ting Cao
- College of Medical Engineering, Key Laboratory for Medical Functional Nanomaterials, Jining Medical University Jining 272067 China
| | - Su-Ning Wei
- College of Medical Engineering, Key Laboratory for Medical Functional Nanomaterials, Jining Medical University Jining 272067 China
| | - Hao-Tian Sun
- College of Medical Engineering, Key Laboratory for Medical Functional Nanomaterials, Jining Medical University Jining 272067 China
| | - Meng Li
- College of Medical Engineering, Key Laboratory for Medical Functional Nanomaterials, Jining Medical University Jining 272067 China
| | - Zuo-Ling Zheng
- College of Medical Engineering, Key Laboratory for Medical Functional Nanomaterials, Jining Medical University Jining 272067 China
| | - Guannan Wang
- College of Medical Engineering, Key Laboratory for Medical Functional Nanomaterials, Jining Medical University Jining 272067 China
| |
Collapse
|
3
|
de Souza Neto LR, Moreira-Filho JT, Neves BJ, Maidana RLBR, Guimarães ACR, Furnham N, Andrade CH, Silva FP. In silico Strategies to Support Fragment-to-Lead Optimization in Drug Discovery. Front Chem 2020; 8:93. [PMID: 32133344 PMCID: PMC7040036 DOI: 10.3389/fchem.2020.00093] [Citation(s) in RCA: 100] [Impact Index Per Article: 25.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2019] [Accepted: 01/30/2020] [Indexed: 12/16/2022] Open
Abstract
Fragment-based drug (or lead) discovery (FBDD or FBLD) has developed in the last two decades to become a successful key technology in the pharmaceutical industry for early stage drug discovery and development. The FBDD strategy consists of screening low molecular weight compounds against macromolecular targets (usually proteins) of clinical relevance. These small molecular fragments can bind at one or more sites on the target and act as starting points for the development of lead compounds. In developing the fragments attractive features that can translate into compounds with favorable physical, pharmacokinetics and toxicity (ADMET-absorption, distribution, metabolism, excretion, and toxicity) properties can be integrated. Structure-enabled fragment screening campaigns use a combination of screening by a range of biophysical techniques, such as differential scanning fluorimetry, surface plasmon resonance, and thermophoresis, followed by structural characterization of fragment binding using NMR or X-ray crystallography. Structural characterization is also used in subsequent analysis for growing fragments of selected screening hits. The latest iteration of the FBDD workflow employs a high-throughput methodology of massively parallel screening by X-ray crystallography of individually soaked fragments. In this review we will outline the FBDD strategies and explore a variety of in silico approaches to support the follow-up fragment-to-lead optimization of either: growing, linking, and merging. These fragment expansion strategies include hot spot analysis, druggability prediction, SAR (structure-activity relationships) by catalog methods, application of machine learning/deep learning models for virtual screening and several de novo design methods for proposing synthesizable new compounds. Finally, we will highlight recent case studies in fragment-based drug discovery where in silico methods have successfully contributed to the development of lead compounds.
Collapse
Affiliation(s)
- Lauro Ribeiro de Souza Neto
- LaBECFar – Laboratório de Bioquímica Experimental e Computacional de Fármacos, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - José Teófilo Moreira-Filho
- LabMol – Laboratory for Molecular Modeling and Drug Design, Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia, Brazil
| | - Bruno Junior Neves
- LabMol – Laboratory for Molecular Modeling and Drug Design, Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia, Brazil
- Laboratory of Cheminformatics, Centro Universitário de Anápolis – UniEVANGÉLICA, Anápolis, Brazil
| | - Rocío Lucía Beatriz Riveros Maidana
- LaBECFar – Laboratório de Bioquímica Experimental e Computacional de Fármacos, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
- Laboratório de Genômica Funcional e Bioinformática, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Ana Carolina Ramos Guimarães
- Laboratório de Genômica Funcional e Bioinformática, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Nicholas Furnham
- Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Carolina Horta Andrade
- LabMol – Laboratory for Molecular Modeling and Drug Design, Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia, Brazil
| | - Floriano Paes Silva
- LaBECFar – Laboratório de Bioquímica Experimental e Computacional de Fármacos, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| |
Collapse
|